20(S)-人参皂苷 C-K
中文名称 | 20(S)-人参皂苷 C-K |
---|---|
中文同义词 | S-人参皂苷CK,人参皂苷C-K,人参皂苷K,20;化合物 K;S-人参皂苷C-K;人参皂苷CK(20(S)-人参皂苷CK,人参皂苷C-K,人参皂苷K,20(S)-人参皂苷C-K);COMPOUND K 人参皂苷CK;人参皂苷 K, 来源于人参;人参皂苷CK对照品,;人参皂苷CK(20(S)-人参皂苷CK |
英文名称 | Ginsenoside CK |
英文同义词 | (20S)-20-(β-D-Glucopyranosyloxy)dammara-24-ene-3β,12β-diol;(20S)-20-O-β-D-Glucopyranosylprotopanaxadiol;20-(β-D-Glucopyranosyloxy)-5α-dammara-24-ene-3β,12β-diol;20-(β-D-Glucopyranosyloxy)dammar-24-ene-3β,12β-diol;IH-901;20(S)-Protopanaxadiol 20-O-D-glucopyranoside;GINSENOSIDE COMPOUND K(P);b-D-Glucopyranoside, (3b,12b)-3,12-dihydroxydaMMar-24-en-20-yl |
CAS号 | 39262-14-1 |
分子式 | C36H62O8 |
分子量 | 622.88 |
EINECS号 | |
相关类别 | 对照品,标准品;植物提取物;植提标准品;对照品;中药对照品;标准品;分析试剂标准品;标准品-对照品;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;标准品-中药标准品;标准品,对照品;标准品 -中药标准品;三萜;分析试剂-对照品;高纯分离试剂-标准品;化工原料 |
Mol文件 | 39262-14-1.mol |
结构式 |
20(S)-人参皂苷 C-K 性质
熔点 | 181~183℃ |
---|---|
沸点 | 723.1±60.0 °C(Predicted) |
密度 | 1.19 |
溶解度 | DMF:10mg/mL; DMSO:10mg/mL; DMSO:PBS (pH 7.2) (1:1):0.5 mg/mL |
酸度系数(pKa) | 12.94±0.70(Predicted) |
形态 | 粉末 |
颜色 | 白色 |
稳定性 | 吸湿性 |
InChIKey | FVIZARNDLVOMSU-SFEJUJENNA-N |
LogP | 5.500 (est) |
COX-2
|
iNOS
|
CYP2C9 32 μM (IC 50 ) |
CYP2A6 63.6 μM (IC 50 ) |
Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and proinflammatory cytokines. Ginsenoside C-K suppresses the expression of proinflammatory cytokines by downregulating the activities of IRAK-1, MAPKs, IKK-α, and NF-κB in LPS-treated murine peritoneal macrophages. Ginsenoside C-K also suppresses the expression of iNOS and COX-2 by inhibiting NF-κB signaling in LPS-stimulated RAW264.7 cells. In zymosan-treated bone-marrow-derived macrophages (BMDMs) and RAW264.7 cells, Ginsenoside C-K inhibits inflammatory responses by negatively regulating the secretion of proinflammatory cytokines, the activation of MAPKs, and the generation of ROS. In addition, anti-inflammatory activity of Ginsenoside C-K has been observed in LPS-stimulated microglial cells. Ginsenoside C-K hinders inflammatory responses by controlling both the generation of ROS and the activities of MAPKs, NF-κB, and AP-1. Ginsenoside C-K, a major metabolite of ginsenosides in the gastrointestinal tract, inhibits NF-κB signaling in a PXR-dependent manner. Ginsenoside C-K is shown to promote recovery of dextran sulfate sodium (DSS) -induced colitis by suppressing NF-κB activation. Ginsenoside C-K significantly reduces TNF-α-induced upregulation of IL-1β and iNOS mRNA levels, and restores the mRNA levels of PXR and CYP3A4 in LS174T cells. Ginsenoside C-K, one of the intestinal metabolites of 20(S)-protopanaxadiol derivatives, exhibits an inhibition against the activity of CYP2C9 in human liver microsomes with an IC 50 value of 32.0±3.6 μM, a weak inhibition against the activity of CYP2A6 in human liver microsomes with an IC 50 value of 63.6±4.2 μM, and an even weaker inhibition against the activity of CYP2D6 in human liver microsomes with an IC 50 value of more than 100 μM.
The weight of the collagen-induced arthritis (CIA) mice increases slowly and is significantly less than that of the normal DBA/1 mice beginning on d 3 after injection of the emulsion. Ginsenoside C-K (28, 56, and 112 mg/kg) mice recover their weight by d 32 after the emulsion injection. Ginsenoside C-K (56 and 112 mg/kg) and Methotrexate (MTX)-treated (2 mg/kg) mice show significantly increased body weight on d 50 as compared with CIA mice. Hind paw-swelling began on d 24 post-immunization. CIA mice are treated from d 28 to d 50. Arthritis scores are measured every 4 d beginning on d 24. Ginsenoside C-K (56 and 112 mg/kg) significantly reduces the arthritis scores of the mice on d 51.
药理药效:抗肿瘤、抗炎、保肝和抗过敏。调节神经系统及免疫系统。